Home
LBPH
LBPH News

Latest Longboard Pharmaceuticals Inc. (LBPH) News on November 22, 2024

Longboard commences Phase III trial of bexicaserin for DEEs seizure treatment

Clinical Trials Arena

9 days ago

Longboard commences Phase III trial of bexicaserin for DEEs seizure treatment

Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)

Business Wire

10 days ago

Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)

Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Business Wire

15 days ago

Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

MT Newswires

a month ago

HC Wainwright Downgrades Longboard Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $60 From $80

Health Care Roundup: Market Talk

The Wall Street Journal

a month ago

Health Care Roundup: Market Talk

Longboard Set to be Acquired by Lundbeck for $2.6B, Stock Soars 52%

Zacks

a month ago

Longboard Set to be Acquired by Lundbeck for $2.6B, Stock Soars 52%

MT Newswires

a month ago

B. Riley Downgrades Longboard Pharmaceuticals to Neutral From Buy, Raises Price Target to $60 From $45

MT Newswires

a month ago

Baird Downgrades Longboard Pharmaceuticals to Neutral From Outperform, Price Target is $60

MT Newswires

a month ago

Truist Securities Downgrades Longboard Pharmaceuticals to Hold From Buy, Price Target Remains $60

Lundbeck to acquire Longboard Pharmaceuticals for $2.6bn

Pharmaceutical Technology

a month ago

Lundbeck to acquire Longboard Pharmaceuticals for $2.6bn

Top 1% Biotech Longboard Scores A $2.6 Billion Deal And Skyrockets To A Record

Investor's Business Daily

a month ago

Top 1% Biotech Longboard Scores A $2.6 Billion Deal And Skyrockets To A Record

Lundbeck to acquire Longboard Pharmaceuticals in $2.6B deal

Yahoo Finance Video

a month ago

Lundbeck to acquire Longboard Pharmaceuticals in $2.6B deal

MT Newswires

a month ago

Baird Downgrades Longboard Pharmaceuticals to Neutral From Outperform, $60 Price Target

MT Newswires

a month ago

Top Midday Gainers

MT Newswires

a month ago

Longboard Pharmaceuticals-H. Lundbeck Deal Undervalues Franchise, Truist Says

MT Newswires

a month ago

Wedbush Downgrades Longboard Pharmaceuticals to Neutral From Outperform, Adjusts Price Target to $60 From $44

Lundbeck to Buy Longboard Pharma in $2.6 Billion Deal

Bloomberg

a month ago

Lundbeck to Buy Longboard Pharma in $2.6 Billion Deal

Why Is Epilepsy Focused Longboard Pharmaceuticals Stock Trading Higher On Monday?

Benzinga

a month ago

Why Is Epilepsy Focused Longboard Pharmaceuticals Stock Trading Higher On Monday?

MT Newswires

a month ago

Sector Update: Health Care

MT Newswires

a month ago

Top Premarket Gainers

MT Newswires

a month ago

Longboard Pharmaceuticals Signs $2.6 Billion Deal to be Acquired by Lundbeck

Denmark's Lundbeck bets on epilepsy drug in $2.6 billion Longboard deal

Reuters

a month ago

Denmark's Lundbeck bets on epilepsy drug in $2.6 billion Longboard deal

Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline

Business Wire

a month ago

Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline

GuruFocus.com

a month ago

Longboard Pharmaceuticals Inc (LBPH) Q2 2024 Earnings Call Highlights: Promising Clinical ...

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Business Wire

2 months ago

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Longboard Pharmaceuticals begins Phase III Dravet syndrome trial

Clinical Trials Arena

2 months ago

Longboard Pharmaceuticals begins Phase III Dravet syndrome trial

Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome

Business Wire

2 months ago

Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome

Longboard Stock Soars on FDA Designations for Epilepsy Drug

Zacks

2 months ago

Longboard Stock Soars on FDA Designations for Epilepsy Drug

MT Newswires

2 months ago

Sector Update: Health Care Stocks Rise in Afternoon Trading

MT Newswires

2 months ago

Longboard Pharmaceuticals Says Potential Dravet Syndrome Treatment Gets Rare Pediatric Disease, Orphan Drug Designations From FDA

Longboard Pharmaceuticals Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Bexicaserin (LP352) in Dravet Syndrome

Business Wire

2 months ago

Longboard Pharmaceuticals Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Bexicaserin (LP352) in Dravet Syndrome

MT Newswires

2 months ago

Wedbush Raises Price Target on Longboard Pharmaceuticals to $44 From $40, Keeps Outperform Rating

MT Newswires

2 months ago

Truist Initiates Longboard Pharmaceuticals at Buy With $60 Price Target

Longboard reports interim data from Phase II extension trial of DEEs treatment

Clinical Trials Arena

2 months ago

Longboard reports interim data from Phase II extension trial of DEEs treatment

MT Newswires

2 months ago

Longboard Pharmaceuticals Reports 'Positive' Interim Results for Potential Epilepsy Treatment

Longboard Pharmaceuticals Announces Positive Interim Analysis Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)

Business Wire

2 months ago

Longboard Pharmaceuticals Announces Positive Interim Analysis Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Business Wire

3 months ago

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Longboard Pharmaceuticals to Participate in Four Upcoming Investor Conferences in September

Business Wire

3 months ago

Longboard Pharmaceuticals to Participate in Four Upcoming Investor Conferences in September

Longboard Pharmaceuticals to Present Late-Breaking and Encore Data at the 15th European Epilepsy Congress

Business Wire

3 months ago

Longboard Pharmaceuticals to Present Late-Breaking and Encore Data at the 15th European Epilepsy Congress

Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on September 16, 2024

Business Wire

3 months ago

Longboard Pharmaceuticals to Host Investor & Analyst Event in New York on September 16, 2024

MT Newswires

4 months ago

B. Riley Adjusts Price Target on Longboard Pharmaceuticals to $45 From $36, Maintain Buy Rating

Is Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) Trading At A 40% Discount?

Simply Wall St.

4 months ago

Is Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) Trading At A 40% Discount?

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Business Wire

4 months ago

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

MT Newswires

4 months ago

Wedbush Adjusts Longboard Pharmaceuticals Price Target to $40 From $42, Maintains Outperform Rating

Longboard Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Business Wire

4 months ago

Longboard Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates

Longboard Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host Corporate Update Call on August 1

Business Wire

4 months ago

Longboard Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host Corporate Update Call on August 1

Longboard Pharmaceuticals (LBPH) Is a Great Choice for 'Trend' Investors, Here's Why

Zacks

4 months ago

Longboard Pharmaceuticals (LBPH) Is a Great Choice for 'Trend' Investors, Here's Why

3 Russell 2000 Growth Stocks That Could Be Worth the Risk

Motley Fool

4 months ago

3 Russell 2000 Growth Stocks That Could Be Worth the Risk

Andreas Halvorsen's Strategic Acquisition in Longboard Pharmaceuticals

GuruFocus.com

4 months ago

Andreas Halvorsen's Strategic Acquisition in Longboard Pharmaceuticals

MT Newswires

4 months ago

Baird Adjusts Price Target on Longboard Pharmaceuticals to $60 From $36, Maintains Outperform Rating

Wall Street Analysts Think Longboard Pharmaceuticals (LBPH) Could Surge 43.7%: Read This Before Placing a Bet

Zacks

4 months ago

Wall Street Analysts Think Longboard Pharmaceuticals (LBPH) Could Surge 43.7%: Read This Before Placing a Bet

Longboard Pharmaceuticals (LBPH) is on the Move, Here's Why the Trend Could be Sustainable

Zacks

4 months ago

Longboard Pharmaceuticals (LBPH) is on the Move, Here's Why the Trend Could be Sustainable

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Business Wire

5 months ago

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag

Zacks

5 months ago

Longboard (LBPH) Up 14% as Epilepsy Drug Gets Breakthrough Tag

MT Newswires

5 months ago

Evercore ISI Raises Price Target on Longboard Pharmaceuticals to $80 From $57, Keeps Outperform Rating

MT Newswires

5 months ago

Longboard Pharmaceuticals Gets FDA Breakthrough Therapy Designation for Seizure Treatment

Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352)

Business Wire

5 months ago

Longboard Pharmaceuticals Receives Breakthrough Therapy Designation for Bexicaserin (LP352)

MT Newswires

5 months ago

Evercore ISI Raises Price Target on Longboard Pharmaceuticals to $57 From $44, Maintains Outperform Rating

MT Newswires

5 months ago

B. Riley Raises Price Target on Longboard Pharmaceuticals to $36 From $30, Maintains Buy Rating

MT Newswires

5 months ago

Wedbush Adjusts Longboard Pharmaceuticals Price Target to $42 From $34, Maintains Outperform Rating

Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)

Business Wire

5 months ago

Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers

GOBankingRates

5 months ago

5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia

Business Insider

5 months ago

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia

The Best Woody Perfume For Women

Insider Monkey

5 months ago

The Best Woody Perfume For Women

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase

Reuters

5 months ago

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase

Insider Monkey

5 months ago

Best Date Night Fragrance in 2024

France's Macron calls snap legislative elections after EU poll blow

AFP

5 months ago

France's Macron calls snap legislative elections after EU poll blow

Dow Jones Futures Due; Apple AI Push, Fed Rate Outlook Lead 8 Big Market Events

Investor's Business Daily

5 months ago

Dow Jones Futures Due; Apple AI Push, Fed Rate Outlook Lead 8 Big Market Events

European Union Vote Delivers Shift to Right, in Blow to French and German Governments

The Wall Street Journal

5 months ago

European Union Vote Delivers Shift to Right, in Blow to French and German Governments

Bangladesh Ecommerce Market Report 2024, Featuring Daraz Bangladesh, Chaldal, Evaly, Pickaboo and Ajkerdeal - Forecasts to 2028

GlobeNewswire

5 months ago

Bangladesh Ecommerce Market Report 2024, Featuring Daraz Bangladesh, Chaldal, Evaly, Pickaboo and Ajkerdeal - Forecasts to 2028

3 Major Product Releases at 3Shape Discover Event

PR Newswire

5 months ago

3 Major Product Releases at 3Shape Discover Event

Flash News: OKX Launches 'Trade and Earn' Campaign Featuring 2,500,000 Ultiverse Tokens

GlobeNewswire

5 months ago

Flash News: OKX Launches 'Trade and Earn' Campaign Featuring 2,500,000 Ultiverse Tokens

EXCLUSIVE: Sunlight Creates Love Note Projections In New Fred Jewelry Collection

WWD

5 months ago

EXCLUSIVE: Sunlight Creates Love Note Projections In New Fred Jewelry Collection

Advantech Releases FWA-3051, The Latest 1U Rackmount Edge Networking Solution with Intel® Xeon® D-2700/2800 Series

PR Newswire

5 months ago

Advantech Releases FWA-3051, The Latest 1U Rackmount Edge Networking Solution with Intel® Xeon® D-2700/2800 Series

Sustainable Construction Practices and Modular Techniques Drive Dry Construction Market to $127.69 Billion by 2029

GlobeNewswire

5 months ago

Sustainable Construction Practices and Modular Techniques Drive Dry Construction Market to $127.69 Billion by 2029

Hydrogen Storage Market Set to Hit $6.8 Billion by 2031, registering a solid CAGR of 23% - Exclusive Report by Coherent Market Insights

GlobeNewswire

5 months ago

Hydrogen Storage Market Set to Hit $6.8 Billion by 2031, registering a solid CAGR of 23% - Exclusive Report by Coherent Market Insights

Shake Shack (SHAK) Rose after Strong Q4 Results

Insider Monkey

5 months ago

Shake Shack (SHAK) Rose after Strong Q4 Results

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Business Wire

6 months ago

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Good Position To Deliver On Growth Plans

Simply Wall St.

7 months ago

Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Good Position To Deliver On Growth Plans

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Business Wire

7 months ago

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

GuruFocus.com

7 months ago

Longboard Pharmaceuticals Inc. (LBPH) Q1 2024 Earnings: Financial and Strategic Developments

MT Newswires

7 months ago

Wedbush Adjusts Longboard Pharmaceuticals' PT to $34 From $32, Keeps Outperform Rating

Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Business Wire

7 months ago

Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Starbucks downgraded, Dollar Tree upgraded: Wall Street's top analyst calls

The Fly

7 months ago

Starbucks downgraded, Dollar Tree upgraded: Wall Street's top analyst calls

MT Newswires

7 months ago

Baird Starts Longboard Pharmaceuticals With Outperform Rating, $36 Price Target

Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15

Business Wire

8 months ago

Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Business Wire

8 months ago

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) is a favorite amongst institutional investors who own 50%

Simply Wall St.

8 months ago

Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) is a favorite amongst institutional investors who own 50%

GuruFocus.com

8 months ago

Longboard Pharmaceuticals Inc Reports Full Year 2023 Financial Results

Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates

Business Wire

8 months ago

Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Business Wire

9 months ago

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Business Wire

10 months ago

Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Leslie’s, Inc. (NASDAQ:LESL) Q1 2024 Earnings Call Transcript

Insider Monkey

10 months ago

Leslie’s, Inc. (NASDAQ:LESL) Q1 2024 Earnings Call Transcript

Longboard Pharmaceuticals to Present at Two Upcoming Investor Conferences in February

Business Wire

10 months ago

Longboard Pharmaceuticals to Present at Two Upcoming Investor Conferences in February

ZIM Integrated Shipping Services (ZIM) Ascends While Market Falls: Some Facts to Note

Zacks

10 months ago

ZIM Integrated Shipping Services (ZIM) Ascends While Market Falls: Some Facts to Note

Allegiant (ALGT) to Report Q4 Earnings: What's in Store?

Zacks

10 months ago

Allegiant (ALGT) to Report Q4 Earnings: What's in Store?

Institutions profited after Star Bulk Carriers Corp.'s (NASDAQ:SBLK) market cap rose US$66m last week but individual investors profited the most

Simply Wall St.

10 months ago

Institutions profited after Star Bulk Carriers Corp.'s (NASDAQ:SBLK) market cap rose US$66m last week but individual investors profited the most

Provident Financial Services Inc Reports Mixed Results Amid Economic Challenges

GuruFocus.com

10 months ago

Provident Financial Services Inc Reports Mixed Results Amid Economic Challenges

Paragon 28 Launches the Mister Tendon™ Harvester System – The First and Only Minimally Invasive Harvesting System for FHL and FDL Tendon Transfer Procedures

Business Wire

10 months ago

Paragon 28 Launches the Mister Tendon™ Harvester System – The First and Only Minimally Invasive Harvesting System for FHL and FDL Tendon Transfer Procedures

Peoples Bancorp Inc. (NASDAQ:PEBO) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Simply Wall St.

10 months ago

Peoples Bancorp Inc. (NASDAQ:PEBO) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Share on Social Networks: